The Oxford Academic Health Science Network’s Clinical Innovation Adoption (CIA) programme helps implement evidence-based innovation in line with NHS needs, improving patient outcomes and reducing NHS costs.
It supports changes in practice and improvement, building region-wide capability and capacity and enhancing cost-effectiveness. The programme works closely with NHS leaders in primary and secondary care, commissioners, clinical innovators, industry partners and others in line with both regional and national priorities.
Using a tried and trusted ten-step process, the programme has evaluated more than 300 innovations, taking account of potential benefits, impact on patient experience, local priorities and ease of adoption. Expert input from the team covers building the case for change, evaluation, supporting implementation and understanding and overcoming barriers to adoption.
As a result, over 30 sustainable and wide-ranging innovations have been implemented across medicines, medical devices, digital and system transformation. There are currently at least 20 active projects. Read more about these in the National programmes and Local programmes sections – and find out more about members of the team here.
The CIA programme also runs a Masters-level course for clinical innovators – more than 200 people have benefited from this collaboration with Bucks New University and Health Education England.
Neil Dardis, Chief Executive of Frimley Health NHS Foundation Trust, Chairs the CIA Oversight Group. He says: “The Oxford AHSN Clinical Innovation Adoption programme really makes a difference and has a positive impact on patient outcomes. This is founded on the strong connections the team has developed with clinicians. The training opportunities they have secured are really important in enabling our clinicians and teams to innovate and deliver improvement, as well as achieving sustainability and momentum.”
Further information: [email protected]